L

LifeStance Health

Nationwide in-person and telehealth mental care

Head of Research

Full-Time
$210k - $225k/yr+ Bonus plan + Equity potential
Expert
Master's, PhD
Remote in USA
RemotePeriodic travel may be required for enterprise meetings, research collaborations, conferences, leadership discussions, or operational engagement.
Academic & Institutional ResearchMedical Research
No H1B Sponsorship

About the job

Requirements
  • A doctoral degree such as a PhD, PsyD, MD, DrPH, ScD, or equivalent terminal degree in psychology, psychiatry, behavioral health, public health, health services research, statistics, data science, epidemiology, or a related field; a master's degree with significant equivalent research leadership experience may be considered.
  • At least 10 years of progressive experience in clinical research, behavioral health research, health services research, outcomes research, quality improvement, data analytics, or a related healthcare research function.
  • At least 5 years of leadership experience managing research teams, cross-functional research programs, external collaborators, or complex multi-stakeholder research initiatives.
  • Demonstrated experience designing, analyzing, interpreting, and disseminating clinical or healthcare outcomes research using real-world data, EHR-derived data, claims data, survey data, or measurement-based care data.
  • Experience developing manuscripts, conference submissions, white papers, executive research summaries, or external publications.
  • Human subjects research training, IRB familiarity, or equivalent research compliance training is required or must be completed upon hire.
  • Expertise in research strategy, study design, outcomes methodology, data interpretation, and evidence generation.
  • Strong understanding of behavioral health care delivery, measurement-based care, quality improvement, and clinical governance.
  • Ability to translate complex data and research findings into clear, actionable recommendations for clinical, operational, and executive audiences.
  • Executive communication, publication development, stakeholder influence, and cross-functional leadership skills.
  • High standards for research ethics, data integrity, privacy, equity, and compliance.
  • Qualified candidates must be legally authorized to be employed in the United States.
  • Demonstrated awareness, inclusivity, sensitivity, humility, and experience working with individuals from diverse ethnic backgrounds, socioeconomic statuses, sexual orientations, gender identities, and other aspects of culture.
  • Ability to meet the role's physical requirements, including lifting and/or moving objects up to 25 pounds.
  • Reliable internet access and a quiet, distraction-free, dedicated HIPAA-compliant workspace are required for remote work.
Responsibilities
  • Develop and lead the enterprise research strategy, including annual research priorities, publication roadmap, governance processes, and standards for ethical, compliant research execution.
  • Oversee analyses of clinical, operational, and measurement-based care data to produce actionable insights regarding access, engagement, quality, safety, clinical effectiveness, and patient outcomes, guided by Clinical Excellence.
  • Establish publication standards and oversee development of manuscripts, white papers, conference abstracts, annual outcomes reporting, and external-facing research narratives.
  • Build scalable research operations, including project intake, prioritization, study design support, documentation, data request workflows, IRB and regulatory coordination, and reporting cadence.
  • Partner with Clinical Excellence, Quality, Legal/Compliance, Privacy, Data Insights, Informatics, Practice Operations, Strategy, and Finance to ensure research initiatives are strategically aligned, operationally feasible, and clinically meaningful.
  • Develop and manage research collaborations with academic institutions, health systems, professional organizations, vendors, and external experts to advance evidence generation and dissemination.
  • Collaborate with Clinical Excellence to translate research insights into clinical quality improvement priorities, measurement frameworks, and evidence-based recommendations that support clinicians and improve patient care.
  • Lead and develop research staff, consultants, and matrixed contributors by setting priorities, establishing clear expectations, providing coaching, and maintaining accountability for high-quality deliverables.
  • Ensure research activities align with applicable laws, regulations, privacy requirements, ethical standards, IRB expectations, and company policies governing data use, patient confidentiality, and external dissemination.
  • Prepare executive-ready updates, dashboards, recommendations, and presentations for senior leadership, governance committees, and other internal stakeholders.
  • Own cross-functional and enterprise-level research initiatives, including publication timelines, outcomes reporting, external collaborations, research governance, and implementation of scalable research processes.
  • Set research priorities, determine study design recommendations, shape publication strategy, and translate data into research deliverables, seeking input or approval for decisions involving legal, regulatory, privacy, patient safety, reputational, vendor, or material enterprise resource implications.
  • Partner with Legal, Compliance, Privacy, Quality, and the CMO to mitigate risks before research activities, analyses, or publications are implemented or released.
  • Periodically travel for enterprise meetings, research collaborations, conferences, leadership discussions, or operational engagement.
Desired Qualifications
  • Experience in a large, multi-site, multi-state behavioral health, outpatient mental health, or healthcare delivery organization.
  • Peer-reviewed publication record, grant experience, academic partnership experience, or national conference presentation experience.
  • Experience with measurement-based care, patient-reported outcomes, real-world evidence, health equity research, value-based care, or predictive analytics.
  • Experience managing external research partnerships, vendors, consultants, or data collaboration agreements.

About the company

LifeStance Health provides mental health care across the United States through a network of about 4,000 clinicians, including psychiatrists, psychologists, and licensed therapists. With more than 450 centers in 31 states, it offers both in-person and telehealth appointments, making care flexible and accessible. The company focuses on personalized care plans tailored to each client’s needs and accepts most insurance plans to keep services affordable. Core services include diagnosis, therapy, and medication management delivered by a team of qualified professionals who work with individuals, families, and groups. Compared with others in the space, LifeStance leverages a large nationwide footprint, a mixed delivery model (in-person and telehealth), and a commitment to individualized treatment plans to reach a broad audience efficiently. Its goal is to improve access to trusted, affordable, and personalized mental healthcare so people can lead healthier, more fulfilling lives.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Bellevue, Washington

Founded

2017

Get referred to LifeStance Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 26% to $435.4 million; EBITDA nearly doubled to $66 million.
  • LifeStance raised 2026 revenue guidance to $1.685-$1.725 billion after August 6.
  • A $100 million buyback and $49 million Q2 repurchases signal cash generation.

What critics are saying

  • Strong v. LifeStance final approval hearing on October 16, 2026 threatens fresh privacy headlines.
  • Tuck-in acquisitions, including $12.7 million year-to-date spending, can distract clinicians and managers.
  • A sustained payer reimbursement reset would crush LifeStance's visit-margin model by 2027.

What makes LifeStance Health unique

  • LifeStance's 8,542 clinicians and 33-state outpatient network create dense local referral advantages.
  • Its in-person-plus-telehealth model captures patients needing continuity, convenience, and payer breadth.
  • Management's payer partnerships lifted reimbursement per visit 6% in Q2 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Parental Leave
  • Paid Vacation
  • Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

1%
Ropes & Gray
Sep 30th, 2026
Ropes & Gray Advised on LifeStance Health Group’s $275 Million Secondary Public Offering | News & Events | Ropes & Gray LLP

Ropes & Gray advised LifeStance Health Group, TPG, and Summit Partners on a $275M secondary public offering of 22.25M shares at $12.35 each.

WallStreetZen
Sep 2nd, 2026
1 stock quietly hitting new highs.

1 stock quietly hitting new highs. By Mijuško Šibalić, Stock Market Writer and Stock Researcher September 2, 2026 10:57 PM PDT Dear WallStreetZen Member, This week, its Smart Leverage Alert centers on LifeStance Health (LFST). LifeStance Health is one of the largest outpatient mental-health providers in the country - a national network of therapists and psychiatrists delivering in-person and virtual care. After years of scaling, the business has just crossed an important line: it's now profitable, and the market is rewarding the turn. In its most recent quarter, reported August 6, LifeStance posted adjusted earnings of $0.06 per share, ahead of the $0.03 estimate, as revenue reached roughly $1.58 billion. More telling is the trajectory: both revenue and earnings are forecast to grow significantly faster than the broader Medical Care Facilities industry. This isn't a cheap stock, and WallStreetZen is not pretending it is. It trades at a premium because it's growing into a large, underserved market - and the price action agrees, with shares up more than 120% over the past year and pressing new highs. Wall Street is lined up behind it too: of the six analysts covering LFST, the consensus is a Strong Buy recommendation, with none rating it a sell. Its Zen Ratings model confirms the strength. LFST earns an A rating, which amounts to a Strong Buy recommendation, landing in the top 4% of more than 4,600 stocks. It's the #3-ranked stock in the A-rated Medical Care Facilities industry. Looking at the Component Grades that shape the overall grade, LFST ranks in the top 14% for Momentum, the top 2% for Sentiment, and the top 1% for Growth - a fast-growing business with real institutional conviction behind it. Its logic. With Zen Options Essentials, WallStreetZen use "Smart Leverage" - Deep-In-The-Money options that let you control shares for a fraction of the cost, with your maximum risk strictly defined from day one. The "Smart Leverage" Setup: LFST long call. Given the strong fundamental case and the momentum building behind LifeStance, here's how WallStreetZen is structuring the trade using Smart Leverage - Deep-In-The-Money calls that move nearly dollar-for-dollar with the stock, but with strictly defined risk from day one. Instead of committing about $5,040 to own 400 shares outright, four Deep-In-The-Money Calls let you control those same shares for about $1,352. * The Play: $10 Strike Call (Expiring Mar 19, 2027), 4 contracts * Delta: 0.8333 - Right in its sweet spot. This option moves nearly dollar-for-dollar with the stock. You get the upside with significantly less capital at risk. * Intrinsic Value: ~82% - More than four-fifths of what you pay is real value, not time decay. This is what separates a Smart Leverage setup from the kind of speculative options trades that blow up amateur accounts. * Leverage Multiple: 2.14x - Every dollar moves 2.1x harder than the stock, while the deep ITM strike still keeps meaningful downside protection versus a naked speculative call. * The Target: For this position to double (+100%), LFST only needs to reach approximately $16.76 - a roughly 29% move in the stock that produces a 100% return on the option premium. Why Options Over Shares? A 29% move in LFST stock would be a solid return for shareholders. In these Deep-In-The-Money options, that same move has the potential to double your investment while putting only about $1,352 at risk instead of $5,040. That's the power of Smart Leverage: stock-like upside with a fraction of the capital and strictly defined risk from day one. What to do next? LFST is just one of the setups its Zen Options Essentials TradeFinder identified this week. And the best part? You don't need to spend hours doing research to find these trades. The TradeFinder does the heavy lifting - scanning for Deep-In-The-Money options with the optimal Delta, the right Intrinsic Value, and the right Leverage Multiple - so you can evaluate a trade like this in minutes. How is that possible? Because the best options trades aren't about picking exotic strategies or timing the market perfectly. They're about finding great stocks...and using Smart Leverage to control your risk while amplifying your upside. EXACTLY what the Zen Ratings model is built to find. EXACTLY what this methodology has been delivering. If you'd like to see how this entire methodology works, start by watching its presentation, "Options Trading with the Zen Ratings." It walks through the Smart Leverage framework, the TradeFinder, and how WallStreetZen identify these opportunities step by step. Or, perhaps you are ready to start using Smart Leverage by becoming a Zen Options Essentials member. Click below to join: Happy Investing, Mijusko Sibalic Senior Writer, Zen Options Essentials (C) 2026 WallStreetZen Company. Stock tools. Stock ideas. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.

Ticker Report
Aug 21st, 2026
Virtus Advisers LLC Acquires New Stake in LifeStance Health Group, Inc. $LFST

Virtus Advisers LLC acquired a new stake in LifeStance Health Group, Inc. (NASDAQ:LFST – Free Report) during the 2nd quarter, Holdings Channel reports. The institutional investor acquired 115,039 shares of the company’s stock, valued at approximately $1,232,000. A number of other large investors also recently bought and sold shares of the company. Assetmark Inc. lifted […]

Yahoo Finance
Aug 15th, 2026
LifeStance Health beats Q2 estimates with $435M revenue, raises full-year guidance to $1.71B

LifeStance Health reported second quarter results that exceeded analyst expectations, with revenue of $435.4 million, a 5% beat on estimates. The mental healthcare provider's adjusted EBITDA of $66.04 million came in 21.9% above forecasts. CEO David Bourdon attributed the strong performance to clinician growth and operational efficiency. The company now employs over 8,500 clinicians and is operating at roughly 70% capacity, suggesting room for further productivity gains. The company raised its full-year revenue guidance to $1.71 billion from $1.66 billion and lifted EBITDA expectations to $225 million. Operating margin improved significantly to 7%, up from negative 0.9% in the prior year period. Management indicated that small acquisitions will help expand into new markets, whilst planned investments in technology and clinician compensation may temporarily pressure margins.

Yahoo Finance
Aug 7th, 2026
LifeStance exceeds Q2 2026 guidance with 26% revenue growth and 15% adjusted EBITDA margin

LifeStance Health reported strong second-quarter 2026 results, exceeding all guided metrics with revenue growth surpassing 26% and adjusted EBITDA margins above 15%. The mental healthcare provider's clinician base has grown to over 8,500 practitioners. Chief executive David Bourdon highlighted the company's operational execution and strong clinician productivity during the earnings call. The results prompted LifeStance to raise its full-year 2026 guidance across all metrics. Monica Prokocki, vice president of finance and investor relations, and chief financial officer Ryan McGroarty also participated in the call. The company's earnings release and presentation are available on its investor relations website. LifeStance attributed its performance to its value proposition resonating with clinicians and the strength of its operating model.